← Back to home

LOCALLY ADVANCED, METASTATIC, OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS

Clinical trials for LOCALLY ADVANCED, METASTATIC, OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS explained in plain language.

Never miss a new study

Get alerted when new LOCALLY ADVANCED, METASTATIC, OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS trials appear

Sign up with your email to follow new studies for LOCALLY ADVANCED, METASTATIC, OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New hope for lung cancer patients who stopped responding to standard therapy

Disease control Not yet recruiting

This study tests two experimental drugs, JS212 and JS111, together in people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation) and has stopped responding to standard targeted therapy. About 35 adults will join to find the safest dose and …

Matched conditions: LOCALLY ADVANCED, METASTATIC, OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS

Phase: PHASE2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control

Last updated May 17, 2026 11:50 UTC

LOCALLY ADVANCED, METASTATIC, OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS

Get alerted when new LOCALLY ADVANCED, METASTATIC, OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS trials appear

New hope for lung cancer patients who stopped responding to standard therapy